Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Tesla Raises Cybertruck Prices by $5,000 in US 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Trump Buys SpaceX Shares After Record IPO 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., April 30, 2018 -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2018, and provide a general business overview on Wednesday, May 9, 2018, at 4:30 p.m. ET (1:30 p.m. PT).
Conference Call Details
The live conference call on Wednesday, May 9, 2018, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 7068059. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact:
Cara Miller
Portola Pharmaceuticals
[email protected]
Media Contact:
Laurie Masonson
Pure Communications
[email protected]
